Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management.
Ansell SM.
Am J Hematol. 2024 Dec;99(12):2367-2378. doi: 10.1002/ajh.27470. Epub 2024 Sep 6.
Allogeneic hematopoietic stem cell transplantation in Philadelphia-negative adult ALL: myeloablative, non-myeloablative, and beyond.
Hwang YY, Mohty M, Chim CS.
Hematology. 2015 Mar;20(2):61-71. doi: 10.1179/1607845414Y.0000000175. Epub 2014 Jul 3.
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Cooper JP, Storer BE, Granot N, Gyurkocza B, Sorror ML, Chauncey TR, Shizuru J, Franke GN, Maris MB, Boyer M, Bruno B, Sahebi F, Langston AA, Hari P, Agura ED, Lykke Petersen S, Maziarz RT, Bethge W, Asch J, Gutman JA, Olesen G, Yeager AM, Hübel K, Hogan WJ, Maloney DG, Mielcarek M, Martin PJ, Flowers MED, Georges GE, Woolfrey AE, Deeg JH, Scott BL, McDonald GB, Storb R, Sandmaier BM.
Haematologica. 2021 Jun 1;106(6):1599-1607. doi: 10.3324/haematol.2020.248187.
Allogeneic hematopoietic cell transplantation using non-myeloablative ATG/TLI conditioning for lymphomas.
Othman T, Moskoff BN, Esteghamat N, Hoeg RT, Rosenberg AS, Jonas BA, Abedi M, Richman C, Tuscano JM.
Leuk Lymphoma. 2022 Jan;63(1):231-234. doi: 10.1080/10428194.2021.1975190. Epub 2021 Sep 6.
Non-myeloablative hematopoietic stem cell transplantation.
Maris M, Sandmaier BM, Maloney DG, McSweeney PA, Woolfrey A, Chauncey T, Shizuru J, Niederwieser D, Blume KG, Forman S, Storb R.
Transfus Clin Biol. 2001 Jun;8(3):231-4. doi: 10.1016/s1246-7820(01)00137-9.
Current Activity Trends and Outcomes in Hematopoietic Cell Transplantation and Cellular Therapy - A Report from the CIBMTR.
Spellman SR, Xu K, Oloyede T, Ahn KW, Akhtar O, Bolon YT, Broglie L, Bloomquist J, Bupp C, Chen M, Devine SM, El-Jurdi N, Hamadani M, Hengen M, Huppler AH, Jaglowski S, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Perez W, Phelan R, Rizzo D, Saber W, Stefanski HE, Steinert P, Tuschl E, Visotcky A, Vogel R, Auletta JJ, Shaw BE, Allbee-Johnson M.
Transplant Cell Ther. 2025 Aug;31(8):505-532. doi: 10.1016/j.jtct.2025.05.014. Epub 2025 May 19.
Allogeneic Hematopoietic Cell Transplantation with Non-Myeloablative Conditioning and Post-Transplant Cyclophosphamide Prophylaxis in Patients with Reduced Systolic Function.
LeMaistre FI, Tsai HL, Varadhan R, Al-Talib T, Jones R, Ambinder A.
Transplant Cell Ther. 2024 Feb;30(2):208.e1-208.e7. doi: 10.1016/j.jtct.2023.10.011. Epub 2023 Oct 12.
Non-myeloablative transplantation.
Maloney DG, Sandmaier BM, Mackinnon S, Shizuru JA.
Hematology Am Soc Hematol Educ Program. 2002:392-421. doi: 10.1182/asheducation-2002.1.392.
Pre-transplantation vitamin E levels and acute graft-versus-host disease after non-myeloablative allogeneic hematopoietic cell transplantation.
Gjærde LK, Ostrowski SR, Jørgensen NR, Schierbeck F, Andersen NS, Friis LS, Kornblit B, Petersen SL, Schjødt I, Sengeløv H.
Transpl Immunol. 2022 Oct;74:101650. doi: 10.1016/j.trim.2022.101650. Epub 2022 Jun 16.
A Review of Myeloablative vs Reduced Intensity/Non-Myeloablative Regimens in Allogeneic Hematopoietic Stem Cell Transplantations.
Atilla E, Ataca Atilla P, Demirer T.
Balkan Med J. 2017 Jan;34(1):1-9. doi: 10.4274/balkanmedj.2017.0055. Epub 2017 Jan 5.
